touchMEETING HIGHLIGHTS A voyage of discovery: Exploring the latest evidence for 1q21+
Highlights from a sponsored symposium at the 4th European Myeloma Network Meeting, exploring data and controversies surrounding 1q21+.
Dr Martin Kaiser introduces the agenda and provides an overview of 1q abnormalities in multiple myeloma.
Dr Mattia D’Agostino presents the case supporting 1q21+ to be considered a high risk feature in multiple myeloma.
Dr Cyrus Khandanpour argues that there is still insufficient evidence to support gain of 1q alone as a high-risk factor.
Drs Martin Kaiser and Mattia D’Agostino discuss how 1q21+ plays a role in their assessment of risk in newly-diagnosed patients.
Dr Mattia D’Agostino considers the utility and timing of 1q21+ testing in clinical practice.
Drs Martin Kaiser and Mattia D’Agostino discuss the clinical utility of repeat FISH panel testing during the disease course for RRMM.
Dr Martin Kaiser dives into the clinical data from Phase 3 trials in RRMM that evaluated outcomes according to 1q21+ status.
Drs Martin Kaiser and Mattia D’Agostino discuss the treatment of 1q21+ patients at diagnosis and relapse.
Drs Martin Kaiser and Mattia D’Agostino respond to questions from the symposium audience.
Overview & Learning Objectives
Overview
Highlights from a Sanofi-sponsored satellite symposium at the 4th European Myeloma Network Meeting. Three leading experts discuss the latest evidence around 1q21+ in multiple myeloma.
Learning Objectives
After watching this activity, participants should be better able to:
- Recognize the association between 1q21+ and poor disease outcomes in multiple myeloma.1
- Recall guideline recommendations to test for gain of 1q at diagnosis and relapse.2-4
- Consider how 1q21+ may influence treatment decisions for newly-diagnosed patients as well as those with relapsed or refractory multiple myeloma (RRMM).
- Evaluate evidence from randomized clinical trials that analyzed treatment efficacy with respect to 1q21+ status.
Faculty & Disclosures
Dr Martin Kaiser
The Institute of Cancer Research and Royal Marsden Hospital, London, United Kingdom
Martin Kaiser, MD, FRCP, FRCPath is a Consultant Haematologist at The Royal Marsden and a Clinical Scientist at The Institute for Cancer Research.
Dr Martin Kaiser discloses: Honoraria from: Abbvie, BMS/Celgene, Janssen, Takeda and Sanofi. Advisory fees from: Abbvie, BMS/Celgene, Janssen, Pfizer, GSK and Seattle Genetics. Research support from: BMS/Celgene and Janssen. Travel support from: Takeda, Janssen.
Dr Mattia D’Agostino
University of Turin, Turin, Italy
Mattia D’Agostino, MD, is Assistant Professor in the Myeloma Unit, Division of Haematology, at the University of Turin.
Dr Mattia D’Agostino discloses: Honoraria from: GSK, Janssen and Sanofi. Advisory fees from: BMS, GSK and Sanofi. Research support from: Janssen.
Dr Cyrus Khandanpour
University Medical Center Schleswig-Holstein, Kiel, Germany
Cyrus Khandanpour, MD, MBA, is Deputy Director of the Department of Haematology and Oncology at the University Hospital Schleswig-Holstein.
Dr Cyrus Khandanpour discloses: Honoraria from: Janssen, Sanofi, BMS, Amgen and GSK. Advisory fees from: Research support from: Janssen, Sanofi, BMS, Amgen and GSK. Research support from: Janssen, Sanofi, BMS, Amgen and GSK.
Downloads
View and download resources from this activity to support your learning, or share with your HCP colleagues.
References
- Abdallah N, Greipp P, Kapoor P, et al. Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. Blood Adv. 2020;4(15):3509-3519.
- Dimopoulos MA, Moreau P, Terpos E, et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(3):309-322.
- NCCN Guidelines for Multiple Myeloma V 3.2023.
- Sonneveld P, Avet-Loiseau H, Lonial S, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016;127(24):2955-62.
